Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | MicrobiomeTrials← Back to trialsNCT07811622
Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-09Est. Completion: 2027-12
Enrollment target: 24 participants Locations- The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Other microbiome trials you might be interested in
Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patient…
Boston, United StatesEst. completion Feb 5, 2025
Prostate Cancer
The goal of this clinical research study is to learn if a prostate implant (brachytherapy) can help to control intermedi…
Houston, United StatesEst. completion Sep 30, 2027
Phase 3
Recruiting
Chronic Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult pat…
Los Angeles, United StatesEst. completion Dec 2026